Filing Flows › Industrials › 20/20 Biolabs (AIDX)
20/20 Biolabs (AIDX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · 20/20 Biolabs (AIDX) Q2 2026 earnings results →
Q2 2026 Revenue up 36% year over year to $731K · 206¢ of every $1 of revenue lost · operating margin -170.3%
20/20 Biolabs made $731K in Q2 2026 (+36% Y/Y): OneTest $696K, BioCheck $35K. Operating margin -170.3%, net loss $1.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $731K in Q2 2026, up 37% year over year and up 107% from the previous quarter. OneTest was the largest line at 95% of revenue. OneTest added $223K year over year (up 47%), 114% of the total change. BioCheck declined 15%.
Gross margin was 41.7%, up 11.2 points from a year earlier. Operating costs exceeded revenue by $1.2M, an operating margin of -170.3%. Operating expenses grew 54% against revenue growth of 37%. The fastest-growing cost line was SG&A (+58%). The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $2.2M loss.
Operating cash flow was −$605K. Non-cash charges added back $12K of depreciation and amortization and $371K of share-based compensation. Working capital and other items added $517K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $731K | +36% | -170.3% | −$1.5M | −$605K |
| Q1 2026 | 10-Q | May 20, 2026 | $353K | -36% | -408.4% | −$2.2M | −$1.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About 20/20 Biolabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
In its own words, from its 8-K, filed Aug 17, 2026.
20/20 Biolabs against its Services-Testing Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +11%. Operating margin: -170.3% against the peers' median -3.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AIDX 20/20 Biolabs | Q2 2026 | $731K | +36% | -170.3% |
| ULS UL Solutions | Q3 2026 | $823M | +5% | 19.7% |
| NEO Neogenomics | Q3 2026 | $209M | +11% | -3.8% |
Source: 20/20 Biolabs 10-Q on SEC EDGAR · CIK 1139685 · Services-Testing Laboratories
13F: who owns AIDX and who is buying
More on AIDX
History
Every quarter: Q2 2026 results · Q1 2026 results